Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)

BACKGROUND: The combination of aclidinium bromide, a long-acting anticholinergic, and formoterol fumarate, a long-acting beta(2)-agonist (400/12 μg twice daily) achieves improvements in lung function greater than either monotherapy in patients with chronic obstructive pulmonary disease (COPD), and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Bateman, Eric D., Chapman, Kenneth R., Singh, Dave, D’Urzo, Anthony D., Molins, Eduard, Leselbaum, Anne, Gil, Esther Garcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531806/
https://www.ncbi.nlm.nih.gov/pubmed/26233481
http://dx.doi.org/10.1186/s12931-015-0250-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531806/
https://www.ncbi.nlm.nih.gov/pubmed/26233481
http://dx.doi.org/10.1186/s12931-015-0250-2

Ejemplares similares